Evidence from lung cancer models suggests that ICAM1 present on cancer cells plays a coordinating role in immune anti-tumor responses.[51] In a murine model, UCN2 has been demonstrated to promote the initiation and progression of prostate tumors through its inhibitory effect on apoptosis.[52] Currently, there is a lack of research on the prognostic relevance of these core genes in ccRCC immunotherapy, which may be a direction for further investigation and expansion. The gene discussed is ICAM1; the disease is prostate neoplasm.